Testing of Middle East Respiratory Syndrome Coronavirus Replication Inhibitors for the Ability To Block Viral Entry
Qi Liu(East China University of Science and Technology), Shibo Jiang(Shanghai Medical College of Fudan University), Lanying Du(Georgia State University), Zhiwu Sun(Shanghai Medical College of Fudan University), Shuai Xia(Shanghai Medical College of Fudan University), Lu Lu(Shanghai Medical College of Fudan University), Qian Wang(Shanghai Medical College of Fudan University)
Cited by 45
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
|Frontiers in Microbiology|2020|442
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
|Nature Communications|2014|400